

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY,
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,
Patent Owner.

Case No. IPR2018-01425
Patent No. 9,890,210 B2

PETITIONER'S SUPPLEMENTAL BRIEF
(REGARDING *FOX FACTORY, INC. v. SRAM, LLC*)

Table of Contents

I. Introduction.....1

II. Legal Standard for Presumption of Nexus1

III. Teva Failed to Meet Its Burden of Establishing that Ajoyv[®] and
Emgality[®] Are Coextensive with the Challenged Claims3

 A. Unclaimed Sequence and Mutations Materially Impact
 Function.....3

 B. Other Unclaimed Features Materially Impact Function5

IV. No Nexus Exists Outside of the Alleged Presumption.....6

V. The Alder License Further Demonstrates Lack of Nexus.....7

VI. Conclusion7

GLOSSARY

ADCC	Antibody-dependent cellular cytotoxicity
CDC	Complement-dependent cytotoxicity
CDR	Complementarity-determining region
FDA	U.S. Food and Drug Administration
IPR	<i>Inter partes</i> review
<i>Italicized text</i>	Emphasis added unless otherwise indicated
Lilly or Petitioner	Eli Lilly and Company
pM	picomolar
Teva or Patent Owner	Teva Pharmaceuticals International GmbH
'210 patent	U.S. Patent No. 9,890,210
'614 patent	U.S. Patent No. 9,340,614 (Ex. 1001 in IPR2018-01422)
'951 patent	U.S. Patent No. 9,266,951 (Ex. 1001 in IPR2018-01423)
'881 patent	U.S. Patent No. 9,346,881 (Ex. 1001 in IPR2018-01424)
'794 patent	U.S. Patent No. 8,007,794 (Ex. 2024)

I. Introduction

In *Fox Factory, Inc. v. SRAM, LLC*, the Federal Circuit reaffirmed and clarified that a patentee bears the burden of establishing a presumption of nexus, which requires demonstrating that a product cited for secondary considerations is “coextensive” with the challenged claims. 944 F.3d 1366, 1373 (Fed. Cir. 2019). The court rejected the patentee’s attempt to broaden the coextensiveness requirement to an inquiry of whether the claims “cover” the cited products. *Id.* at 1377.

For nexus in this case, Teva relied solely on the presumption. Sur-reply, 25. Like the patentee in *Fox Factory*, Teva advanced the legally deficient argument that its claims merely “cover[]” Ajovy[®] and Emgality[®]. *Id.*; POR, 45; Ex. 2225, ¶102; Paper 69, 63. Teva failed to satisfy the coextensiveness requirement because these products have numerous features that “materially impact” their functionality but are not recited as limitations. *Fox Factory*, 944 F.3d at 1375-76. Indeed, it is undisputed that the specific, optimized sequences of Ajovy[®] and Emgality[®] materially impact their function, but the challenged claims do not claim any of the optimized sequences and instead broadly recite antibodies without *any* requirement for amino acid sequence. Thus, *Fox Factory* further confirms that nexus is lacking for Teva’s purported secondary considerations.

II. Legal Standard for Presumption of Nexus

Fox Factory reaffirmed that a patentee bears the burden of establishing a

presumption of nexus. *Fox Factory*, 944 F.3d at 1373, 1378 (citing *WMS Gaming Inc. v. Int'l Game Tech.*, 184 F.3d 1339, 1359 (Fed. Cir. 1999)). If the patentee fails to establish the presumption, the petitioner has no burden of rebuttal. *Id.* at 1375. When a product is covered by more than one patent, the patentee has the burden to show that the secondary considerations are due to the challenged claims rather than the other patents. *Id.* (citing *Therasense, Inc. v. Becton, Dickinson & Co.*, 593 F.3d 1289, 1299 (Fed. Cir. 2010)).

In *Fox Factory*, the nexus deficiency arose from overbroad genus claims, not the inclusion of a claimed part within a whole product. The patentee established that thirteen bicycle chainring products were “covered” by the claims, and the secondary considerations evidence *pertained to those chainrings* (not larger products like bicycles, cranksets, or drivetrains). *Id.* at 1371. Those chainring products, however, contained multiple features that “materially impact[ed]” their functionality but were not recited as limitations in the challenged claims. *Id.* at 1375-76. Nexus could not be presumed because the claims were not limited to those material features—and thus were not coextensive with the chainring products. *Id.*

Fox Factory's adherence to the coextensiveness requirement parallels other requirements for secondary considerations. For example, when a patentee fails to establish that other embodiments within the scope of the claims would perform “in the same manner” as a cited product, nexus is likewise lacking due to overbroad

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.